Guobang Pharma Ltd. (SHA:605507)

Market Cap	15.06B +36.2%
Revenue (ttm)	5.94B +4.0%
Net Income	872.95M +24.3%
EPS	1.57 +24.6%
Shares Out	552.99M
PE Ratio	17.36
Forward PE	n/a
Dividend	0.61 (2.18%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,447,200
Average Volume	4,079,781
Open	27.02
Previous Close	27.24
Day's Range	26.50 - 27.23
52-Week Range	18.53 - 29.98
Beta	0.39
RSI	49.39
Earnings Date	Mar 28, 2026

About Guobang Pharma

Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 115 countries and regions worldwide. Guobang Pharma Ltd. was founded in 1996 and is based in Xinchang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,003
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605507

Financial Performance

In 2024, Guobang Pharma's revenue was 5.89 billion, an increase of 10.12% compared to the previous year's 5.35 billion. Earnings were 781.60 million, an increase of 27.61%.